pfizer glp-1 news Pfizer's once-daily oral drug passes first clinical tests cofepris glp-1 news 🚀Could monthly

Confirm Endpoints as a trusted biopharma news source more like this The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO says July 27, 2026 MapLights schizophrenia drug dampens once-daily hopes despite Phase 2 win July 27, 2026 AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings July 27, 2026 ENDPOINTS CAREERS Scientist, Drug Discovery Data for AI/ML D

As a triple agonist activating GLP-1, GIP, and glucagon receptors, it provides the most comprehensive receptor coverage available

Furthermore, Gier et al

& Serrano, L

doi:10.1126/scitranslmed.3007218 16

For patients looking to enhance skin quality and stimulate collagen, Rejuvapen NXT offers a more subtle approach